in € million | Q4 2021 | Q3 2021 | Q4 2020 | Q-Q Δ | Y-Y Δ | |
Total revenues |
52.9
|
41.2
|
36.0
|
28 %
|
47 %
| |
Monjuvi product sales |
20.5
|
18.6
|
14.1
|
10 %
|
45 %
| |
Royalties |
23.2
|
17.0
|
12.1
|
36 %
|
92 %
| |
Licenses, milestones and other |
9.3
|
5.6
|
9.8
|
66 %
|
(5) %
|
in € million* | 2021 | 2020 | Y-Y Δ | |
Total revenues |
179.6
|
327.7
|
(45) %
| |
Product sales |
66.9
|
18.5
|
>100%
| |
Royalties |
65.6
|
42.5
|
54 %
| |
Licenses, milestones and other |
47.2
|
266.7
|
(82) %
| |
* Differences due to rounding. |
Amounts in million | 2022 Financial Guidance | 2022 Guidance Insights |
Monjuvi U.S. Net Product Sales | US$ 110m to 135m | 100% of Monjuvi U.S. product sales are recorded on MorphoSys' income statement and related profit/loss is split 50/50 between MorphoSys and Incyte. |
Gross Margin for Monjuvi U.S. Net Product Sales | 75% to 80% | 100% of Monjuvi U.S. product cost of sales is recorded on MorphoSys' income statement and related profit/loss is split 50/50 between MorphoSys and Incyte. |
R&D expenses | € 300m to 325m | 2022 growth over 2021 will be driven primarily by investment in ongoing pivotal phase-3 studies, excluding transaction/restructuring/other charges related to Constellation acquisition recorded in 2021. |
SG&A expenses | € 155m to 170m |
51% to 56% of mid-point of SG&A expenses represents Monjuvi U.S. selling costs of which 100% are recorded in MorphoSys' income statement. Incyte reimburses MorphoSys for half of these selling expenses.
For 2022, we anticipate a year-over-year decline in SG&A, excluding transaction/restructuring/other charges related to Constellation acquisition recorded in 2021.
|
in € million | 2021 | 2020 | Δ | Q4 2021 | Q4 2020 | Δ | |
Revenues |
179.6
|
327.7
|
(45) %
|
52.9
|
36.0
|
47 %
| |
Product Sales |
66.9
|
18.5
|
>100%
|
20.5
|
14.1
|
45 %
| |
Royalties |
65.6
|
42.5
|
54 %
|
23.2
|
12.1
|
91 %
| |
Licenses, milestones and other |
47.2
|
266.7
|
(82) %
|
9.3
|
9.8
|
(5) %
| |
Cost of Sales |
(32.2)
|
(9.2)
|
251 %
|
(9.5)
|
(9.4)
|
1 %
| |
Gross Profit |
147.4
|
318.5
|
(54) %
|
43.4
|
26.6
|
63 %
| |
Total Operating Expenses |
(655.8)
|
(300.6)
|
>100%
|
(368.4)
|
(101.8)
|
>100%
| |
Research and Development |
(225.2)
|
(139.4)
|
62 %
|
(87.0)
|
(52.8)
|
65 %
| |
Selling |
(121.5)
|
(107.7)
|
13 %
|
(32.5)
|
(32.8)
|
(1) %
| |
General and Administrative |
(78.3)
|
(51.4)
|
52 %
|
(18.2)
|
(14.2)
|
28 %
| |
Impairment of Goodwill |
(230.7)
|
(2.1)
|
>100%
|
(230.7)
|
(2.1)
|
>100%
| |
Operating Profit / (Loss) |
(508.3)
|
18.0
|
>(100)%
|
(325.0)
|
(75.2)
|
>100%
| |
Other Income |
8.2
|
14.6
|
(44) %
|
3.4
|
2.9
|
15 %
| |
Other Expenses |
(6.4)
|
(5.2)
|
23 %
|
(1.7)
|
(2.2)
|
(22) %
| |
Finance Income |
96.6
|
92.0
|
5 %
|
(2.7)
|
31.6
|
>(100)%
| |
Finance Expenses |
(181.5)
|
(96.2)
|
89 %
|
(89.0)
|
5.7
|
>(100)%
| |
Income from Reversals of Impairment |
0.3
|
(0.7)
|
>100%
|
(0.2)
|
0.4
|
>(100)%
| |
Income Tax Benefit / (Expenses) |
76.6
|
75.4
|
2 %
|
34.4
|
20.2
|
70 %
| |
Consolidated Net Profit / (Loss) |
(514.5)
|
97.9
|
>(100)%
|
(381.0)
|
(16.5)
|
>100%
| |
Earnings per Share, Basic and Diluted |
(15.40)
|
-
|
-
|
(11.16)
|
(0.50)
|
>100%
| |
Earnings per Share, Basic |
-
|
3.01
|
-
|
-
|
-
|
-
| |
Earnings per Share, diluted |
-
|
2.97
|
-
|
-
|
-
|
-
| |
Cash and other financial assets (end of period) |
976.9
|
1,244.0
|
(21) %
|
976.9
|
1,244.0
|
(21) %
|
Media Contacts:
Thomas Biegi
Vice President
Tel.: +49 (0)89 / 899 27 26079
thomas.biegi@morphosys.com
|
Investor Contacts:
Dr. Julia Neugebauer
Senior Director
Tel: +49 (0)89 / 899 27 179
julia.neugebauer@morphosys.com
|
Jeanette Bressi
Director, US Communications
Tel: +1 617 404 7816
jeanette.bressi@morphosys.com
|
Myles Clouston
Senior Director
Tel: +1 857 772 0240
myles.clouston@morphosys.com
|
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
MorphoSys AG published this content on 17 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 March 2022 13:50:01 UTC.